Acute atomoxetine treatment of younger and older children with ADHD: A meta-analysis of tolerability and efficacy

BACKGROUND: Atomoxetine is FDA-approved as a treatment of attention-deficit/hyperactivity disorder (ADHD) in patients aged 6 years to adult. Among pediatric clinical trials of atomoxetine to date, six with a randomized, double-blind, placebo-controlled design were used in this meta-analysis. The pur...

Descripción completa

Detalles Bibliográficos
Autores principales: Kratochvil, Christopher J, Milton, Denái R, Vaughan, Brigette S, Greenhill, Laurence L
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2556311/
https://www.ncbi.nlm.nih.gov/pubmed/18793405
http://dx.doi.org/10.1186/1753-2000-2-25

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2556311/
https://www.ncbi.nlm.nih.gov/pubmed/18793405
http://dx.doi.org/10.1186/1753-2000-2-25

Ejemplares similares